BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, May 14, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
June 17, 2002
View Archived Issues
Abbott presents new erythromycins with improved GI tolerability
Read More
New hydroxamic acids with MMP/TNF-alpha-inhibitory activity from Fujisawa
Read More
GSK presents novel inhibitors of IKK-beta
Read More
TNF-alpha production inhibitors in early development at Nikken Chemicals
Read More
Kissei claims SGLT2 inhibitors for use in diabetes and obesity
Read More
New alpha4 integrin-selective cell adhesion inhibitors identified at Japanese lab
Read More
Axokine enters study in obese patients with type 2 diabetes
Read More
Patient enrollment completed in two DAC:opioid phase II trials
Read More
New mechanisms of action reported for Esterom in primary and secondary hyperalgesia
Read More
Neurodex completes phase II/III trial in emotional lability
Read More
Hypoxic cell cytotoxin licensed to KuDOS
Read More
Azapinoindoles with high affinity for the 5-HT2C receptor subtype designed at Pharmacia
Read More
Potent analgesic agents emerge from a series of pyrrole alkylamide analogues
Read More
Strategies in the development of 5-HT2A-selective antagonists
Read More
Safety data for NBI-6024 in adolescent type 1 diabetics support further development
Read More
HIM2 examined for systemic pharmacokinetics in dogs, oral absorption in diabetic patients
Read More
ADA news: dual PPARalpha/gamma agonist has beneficial effects on glucose, lipids
Read More
BMS-298585 exerts both glucose- and lipid-lowering effects in animal models
Read More
Procyon updates development of key product candidates
Read More
Continued expression of anti-HIV-1 antisense RNA up to 24 months after HGTV-43 gene therapy
Read More
InNexus acquires SAT rights to 1F7
Read More
AEterna updates Neovastat progress
Read More
CpG-7909 enters phase I/II in malignant melanoma
Read More
FDA advisory committee sets date to review Vanlev
Read More
Novogen initiates second clinical trial of NV-07a
Read More
Oncolytics to acquire interest in Transition Therapeutics
Read More
Zyprexa approved in E.U. for manic episodes associated with bipolar disorder
Read More
Extina enters phase III for seborrheic dermatitis
Read More